STOCK MARKET BSE NSE

DCGI gives nod to phase-II clinical trial of Colchicine by Hyderabad-based firm for Covid treatment

India is one of the largest producers of Colchicine and if the trial proves successful, it would be available to the patients at an affordable cost.

Published: 12th June 2021 12:37 PM  |   Last Updated: 12th June 2021 12:37 PM   |  A+A-

pills, medicines

For representational purposes (Express Illustrations)

By Express News Service

HYDERABAD: The Council of Scientific & Industrial Research (CSIR) and Hyderabad-based pharmaceutical firm, Laxai Life Sciences, have been given the regulatory approval by Drug Controller General India (DCGI) to undertake a two-arm phase-II clinical trial to assess safety and efficacy of the drug Colchicine, in improvement of clinical outcomes during the treatment of COVID-19 patients. 

Recent clinical studies have reported in leading medical journals about colchicine being associated with a significant reduction in the rates of recurrent pericarditis, post-pericardiotomy syndrome, and peri-procedural atrial fibrillation following cardiac surgery and atrial fibrillation ablation.

Dr Ram Vishwakarma, advisor to DG-CSIR highlighted that colchicine in combination with the standard of care will be an important therapeutic intervention for Covid patients with cardiac co-morbidities and for reducing proinflammatory cytokines, leading to faster recovery.

A number of global studies have confirmed now that cardiac complications during course of COVID-19 infections and post-covid syndrome are leading to loss of many lives, and it is essential to look for new or repurposed drugs.

IICT Director, Dr. S. Chandrasekhar and IIIM Director, Dr. DS Reddy, said that they are looking forward to the outcome of this Phase II clinical efficacy trial on Colchicine, which may lead to life-saving intervention in the management of hospitalized patients. The partner CSIR institutes in this clinical trial are the Indian Institute of Chemical Technology(IICT), Hyderabad and Indian Institute of Integrative Medicine(IIIM), Jammu.

India is one of the largest producers of Colchicine and if the trial proves successful, it would be available to the patients at an affordable cost.

Dr Ram Upadhayay, CEO, Laxai informed, that the enrollment of patients has already begun at multiple sites across India and the trial is likely to be completed in the next 8-10 weeks.

He further added that this drug can be made available to large population of India based on the results of this trial and regulatory approval.

Dr Shekhar C Mande, Director General of CSIR, expressed his happiness on the approval granted to conduct the clinical trial on this approved drug, used for treating gout and related inflammatory conditions. 



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp